

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A method of screening for potential vaccine targets for infectious diseases, comprising:

(a) identifying human host cell gene products selected from the group consisting of: human host cell gene products which are upregulated by a factor of 9 or greater during infection and human host cell gene products which are expressed only during infection;

(b) screening said human host cell gene products for a cytotoxic T lymphocyte (CTL) response in humans immunogenicity;

wherein said gene products which induce a CTL response in humans are immunogenic in said host are potential vaccine targets for infectious disease during which such upregulation or expression occurs.

2. (Currently amended) The method of claim 1, wherein said human host cell gene products which are upregulated by a factor of 9 or greater are expressed at a lower level in uninfected cells than in infected cells of the same type.

3. (Currently amended) The method of claim 1, wherein said human host cell gene products which are upregulated are not expressed at all in uninfected cells of the same type.

4. (Original) The method of claim 1, wherein said infection is infection with human immunodeficiency virus (HIV).

5. (Cancelled)

6. (Currently amended) The method of claim 1, wherein said human host cell gene products of (a) are identified using ordered microarrays of nucleic acids.

7. (Currently amended) The method of claim 1, wherein said human host cell gene products of (a) are identified using subtractive hybridization.

8-23. (Cancelled)